Ittefaq Hospital Trust
Lahore, Punjab Province, 54000, Pakistan
NCT Number: NCT07588828
Post-operative seroma formation remains one of the most common complications following breast cancer surgery. This prospective randomized controlled trial was conducted to evaluate the efficacy of Micronized Purified Flavonoid Fraction (Daflon) in reducing post-operative seroma formation in patients undergoing breast cancer surgery with sentinel lymph node biopsy or axillary lymph node dissection.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Lahore, Punjab Province, 54000, Pakistan
This single-center prospective randomized controlled study was conducted at the Breast Surgery Unit, Ittefaq Hospital Trust, Lahore. Female patients undergoing breast-conserving surgery or mastectomy with sentinel lymph node biopsy or axillary lymph node dissection for breast cancer were included. Participants were randomized into intervention and control groups according to surgical procedure strata. The intervention arm received Daflon 500 mg twice daily for four weeks post-operatively. Outcomes included seroma formation, drain output, and drain removal duration.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients received Daflon 500 mg orally twice daily for four weeks after breast cancer surgery.
Time frame: 8 weeks
reduction of post-operative seroma formation
Ittefaq Hospital trust
Other
EFFECT OF DAFLON (DIOSMIN AND HESPERIDIN) ON POST-OPERATIVE SEROMA FORMATION IN BREAST CANCER SURGERY
Acronym: seroma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06973265
Breast Cancer Surgery, Hemic and Lymphatic Diseases
Kayseri, Turkey (Türkiye)
View Trial DetailsNCT07077421
Breast Cancer Surgery, Central Sensitization
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06087237
Breast Cancer Surgery, Breast Diseases
Al Mansurah, Egypt
View Trial DetailsNCT06970561
Benign Breast Tumors, Breast Cancer Surgery
Wuhan, Hubei, China
View Trial Details